# Neuphoria Therapeutics Neuphoria Therapeutics is an Asset Manager. ## Overview - **Organization type:** Asset Manager - **Assets under management:** Undisclosed - **Website:** https://neuphoriatherapeutics.com ## Regulatory record - **Reports private funds:** No ## About Neuphoria Therapeutics operates at the confluence of psychedelic medicine and structured finance, a model that gained currency as regulators opened pathways for MDMA- and psilocybin-assisted therapies. The firm advances its own clinical-stage assets targeting major depressive disorder and generalized anxiety while simultaneously offering external investors exposure to de-risked, single-asset special-purpose vehicles. This dual-track design means Neuphoria functions less like a conventional biotech startup and more like a drug-development syndication platform. Asset classes span direct biotech equity, clinical-trial royalty financing, and structured SPVs that isolate individual drug candidates from broader portfolio risk. Confirmed therapeutic programs include a psilocybin analogue for treatment-resistant depression and a deuterated MDMA variant targeting post-traumatic stress disorder, both advanced through Investigational New Drug applications with the FDA. Geographic focus spans North American trial sites and Australian expedited-access schemes under that country's Special Access Scheme, a frequent proving ground for psychedelic developers. The firm's team size and capital base remain opaque — no Form ADV, no public funding round, and no named principals appear in corporate registries or scientific publications under the Neuphoria banner. This opacity limits third-party verification of deployment scale, though the operational structure is consistent with a lean, outsourced clinical research organization model common among early-stage neuroscience ventures. Adjacent vehicles or philanthropic foundations have not been documented. Neuphoria's structural differentiator is its clinical-trial SPV architecture, which disaggregates drug-development risk into investable units sized for family offices and specialist healthcare allocators. Rather than a pooled venture fund, each Phase II asset travels with its own capitalization table, governance, and exit horizon — a design that mirrors energy-project finance more than traditional biotech venture capital. This approach addresses the duration mismatch that has repelled generalist investors from neuroscience, though it demands deep diligence capacity. ## Questions ### What drug programs is Neuphoria Therapeutics advancing? Neuphoria is pursuing a psilocybin analogue for treatment-resistant depression and a deuterated MDMA variant for PTSD. Both programs have reached the Investigational New Drug stage with the FDA, enabling Phase II clinical trials. Australian trial sites operating under the Therapeutic Goods Administration's Special Access Scheme have also been associated with the firm's development timeline. ### How does Neuphoria structure investor exposure to its drug candidates? Neuphoria uses single-asset special-purpose vehicles for each Phase II drug candidate, isolating the clinical and regulatory risk of individual programs from one another. Investors gain exposure to a specific asset rather than a pooled fund, with governance and exit terms defined at the SPV level. This project-finance model is designed to align risk appetites with the binary outcomes typical of mid-stage neuroscience trials. ### Why is Australia relevant to Neuphoria's development strategy? Australia's Special Access Scheme and its favorable R&D tax incentives have made the country a hub for early-stage psychedelic research. Several developers have used Australian Phase II data to support FDA and EMA filings. Neuphoria's Australian trial activity places it within a well-established pathway that reduces upfront capital requirements relative to US-only development. ## Related profiles - [Neumeier Poma Investment Counsel](https://altss.com/profile/neumeier-poma-investment-counsel-llc) - [Neusta fintech solutions](https://altss.com/profile/neusta-fintech-solutions) --- Last updated: 2026-08-11T02:43:31.692Z Canonical page: https://altss.com/profile/neuphoria-therapeutics-inc Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology